Do COMT rs4680 and ADORA2A rs5751876 variants affect arousal, stimulant sensitivity, and sleep disturbance?

Genetic variations in the COMT and ADORA2A genes significantly influence the neurochemical pathways that govern sleep architecture, arousal, and responses to central nervous system stimulants.

Mechanistic pathways and interactions

• Enzymatic and receptor kinetics: The COMT rs4680 (Val158Met) G (Val) allele produces a highly active, thermostable enzyme, whereas the A (Met) allele results in a three- to four-fold reduction in enzyme activity, translating to slower prefrontal dopamine clearance. Meanwhile, the ADORA2A rs5751876 (1976T>C) variant alters adenosine A2A receptor availability, receptor function, and overall adenosinergic tone.
• System cross-talk: These pathways directly intersect in the brain, as adenosine A2A receptors act as antagonistic modulators of dopaminergic signaling in striatal circuits, linking adenosine tone directly to dopamine pathway activity.

Clinical and physiological implications

• Sleep architecture: COMT Val/Val homozygotes (rapid dopamine clearance) present with a fragile sleep profile marked by reduced slow-wave sleep (SWS) and lower fast sleep spindle density, whereas Met carriers show robust deep sleep but higher hypersomnia risk. For ADORA2A, the C/C genotype correlates with caffeine-induced sleep disturbance and insomnia-like EEG features, including elevated beta activity and reduced slow-wave parameters.
• Stimulant sensitivity and arousal: ADORA2A T/T carriers exhibit resilience to caffeine-induced insomnia but experience heightened anxiety, emotional arousal, and cravings when exposed to stimulants like caffeine or amphetamines. While COMT alters prefrontal dopamine tone, clinical trials have not yet robustly replicated its utility as a standalone predictor of stimulant response or drug-induced insomnia.

Bottom line

• COMT rs4680 and ADORA2A rs5751876 act as key genetic modifiers of arousal, where COMT primarily shapes baseline prefrontal dopamine clearance and NREM sleep structure, and ADORA2A dictates individual sensitivity to stimulant-induced sleep disruption, anxiety, and neurochemical activation.